These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 7030538

  • 1. Serum and blister fluid immune complexes in bullous pemphigoid: detection with C1q and monoclonal rheumatoid factor.
    Jordon RE, Struve MF, Bushkell LL.
    Clin Exp Immunol; 1981 Jul; 45(1):29-36. PubMed ID: 7030538
    [Abstract] [Full Text] [Related]

  • 2. Immune complexes in pemphigus and bullous pemphigoid.
    Ahmed AR, Moy RL, Chia D, Barnett EV.
    Dermatologica; 1983 Jul; 166(4):175-80. PubMed ID: 6343146
    [Abstract] [Full Text] [Related]

  • 3. Serum and blister fluid anticomplementary activity in pemphigus and bullous pemphigoid. Sucrose density gradient studies.
    Jordon RE, McDuffie FC.
    Proc Soc Exp Biol Med; 1976 Mar; 151(3):594-8. PubMed ID: 768993
    [Abstract] [Full Text] [Related]

  • 4. Bullous pemphigoid: a correlative study of autoantibodies, circulating immune complexes and dermo-epidermal deposits.
    Gomes MA, Dambuyant C, Thivolet J, Bussy R.
    Br J Dermatol; 1982 Jul; 107(1):43-51. PubMed ID: 6809029
    [Abstract] [Full Text] [Related]

  • 5. C1q binding substances in pemphigus and bullous pemphigoid. Detection with a [131I] C1q binding assay.
    Tappeiner G, Heine KG, Kahl JC, Jordon RE.
    Clin Exp Immunol; 1977 Apr; 28(1):40-8. PubMed ID: 324678
    [Abstract] [Full Text] [Related]

  • 6. Localized bullous pemphigoid with negative immunofluorescence.
    Silber JG, Brody N.
    Cutis; 1981 Nov; 28(5):562, 565. PubMed ID: 7030649
    [Abstract] [Full Text] [Related]

  • 7. Functional evidence for complement-activating immune complexes in the skin of patients with bullous pemphigoid.
    Gammon WR, Merritt CC, Lewis DM, Sams WM, Wheeler CE, Carlo JR.
    J Invest Dermatol; 1982 Jan; 78(1):52-7. PubMed ID: 7033396
    [Abstract] [Full Text] [Related]

  • 8. Dermatitis herpetiformis: immune complex detection with C1q and monoclonal rheumatoid factor.
    Jordon RE, Tappeiner G, Kahl JC, Wolff K.
    Br J Dermatol; 1981 Aug; 105(2):159-65. PubMed ID: 7025879
    [Abstract] [Full Text] [Related]

  • 9. The complement system in bullous pemphigoid. III. Fixation of C1q and C4 by pemphigoid antibody.
    Jordon RE, Nordby JM, Milstein H.
    J Lab Clin Med; 1975 Nov; 86(5):733-40. PubMed ID: 1102620
    [Abstract] [Full Text] [Related]

  • 10. Lymphotoxin detected in the blister fluid of bullous pemphigoid patients.
    Jeffes EW, Yamamoto RS, Ahmed AR, Granger GA.
    J Clin Immunol; 1984 Jan; 4(1):31-5. PubMed ID: 6365950
    [Abstract] [Full Text] [Related]

  • 11. Differences in complement-dependent chemotactic activity generated by bullous pemphigoid and epidermolysis bullosa acquisita immune complexes: demonstration by leukocytic attachment and organ culture methods.
    Gammon WR, Inman AO, Wheeler CE.
    J Invest Dermatol; 1984 Jul; 83(1):57-61. PubMed ID: 6376640
    [Abstract] [Full Text] [Related]

  • 12. Ultrastructural localization of in vitro binding sites of circulating anti-basement membrane zone antibodies in bullous pemphigoid.
    Yamasaki Y, Nishikawa T.
    Acta Derm Venereol; 1983 Jul; 63(6):501-6. PubMed ID: 6198839
    [Abstract] [Full Text] [Related]

  • 13. Pemphigoid antibody mediated attachment of peripheral blood leukocytes at the dermal-epidermal junction of human skin.
    Gammon WR, Lewis DM, Carlo JR, Sams WM, Wheeler CE.
    J Invest Dermatol; 1980 Oct; 75(4):334-9. PubMed ID: 7000926
    [Abstract] [Full Text] [Related]

  • 14. C1q-latex assay for immune complexes. Complexes that react with both C1q and monoclonal rheumatoid factor in lupus erythematosus and lung cancer.
    Medof ME.
    J Lab Clin Med; 1982 May; 99(5):678-92. PubMed ID: 6978370
    [Abstract] [Full Text] [Related]

  • 15. Influence of immune-complex size and antigen-antibody ratio on immune complex detection with monoclonal rheumatoid factor and C1q.
    Vanham G, Bloemmen FJ, Ceuppens JL, Stevens EA.
    J Clin Lab Immunol; 1984 Oct; 15(2):63-8. PubMed ID: 6335179
    [Abstract] [Full Text] [Related]

  • 16. The complement system in bullous pemphigoid. I. Complement and component levels in sera and blister fluids.
    Jordon RE, Day NK, Sams WM, Good RA.
    J Clin Invest; 1973 May; 52(5):1207-14. PubMed ID: 4573354
    [Abstract] [Full Text] [Related]

  • 17. Potential role of interleukin-17 in the pathogenesis of bullous pemphigoid.
    Toosi S, Bystryn JC.
    Med Hypotheses; 2010 Apr; 74(4):727-8. PubMed ID: 19945799
    [Abstract] [Full Text] [Related]

  • 18. Detection of circulating immune complexes in cutaneous disease using a monoclonal rheumatoid factor hemagglutination method.
    Jordon RE, Mackel SE, Brumfield H.
    J Clin Lab Immunol; 1981 Jul; 6(1):87-90. PubMed ID: 6790707
    [Abstract] [Full Text] [Related]

  • 19. Increased tryptase and myeloperoxidase levels in blister fluids of patients with bullous pemphigoid: correlations with cytokines, adhesion molecules and anti-basement membrane zone antibodies.
    D'Auria L, Pietravalle M, Cordiali-Fei P, Ameglio F.
    Exp Dermatol; 2000 Apr; 9(2):131-7. PubMed ID: 10772387
    [Abstract] [Full Text] [Related]

  • 20. An in vitro model of immune complex-mediated basement membrane zone separation caused by pemphigoid antibodies, leukocytes, and complement.
    Gammon WR, Merritt CC, Lewis DM, Sams WM, Carlo JR, Wheeler CE.
    J Invest Dermatol; 1982 Apr; 78(4):285-90. PubMed ID: 7040558
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.